药物诱导性线状IgA大疱性皮病:法国69例回顾性药物警戒研究
该研究回顾法国药物警戒网络1985至2017年及专科医师报告的69例药物诱导性线状IgA大疱性皮病(DILAD)病例,用法国归因法系统判定药物因果性。结果显示万古霉素为最常见可疑药物,DILAD与特发性线状IgA大疱性皮病临床差异不大,但前者模拟中毒性表皮坏死松解症(TEN)者更多。
要点
- 万古霉素是DILAD最常见可疑药物,占57%,且更常出现TEN样皮损
- 42%患者有黏膜受累,20%出现模拟TEN的皮损
- 33例单一可疑药物患者中85%内在归因评分为I4
核心结论
- DILAD与特发性线状IgA大疱性皮病无重大临床差异,但前者模拟TEN的患者比例更高。
- 万古霉素在超过半数病例中被怀疑,可能对应更严重的临床表现。
- 研究报告了三个此前未发表的可疑药物。
研究设计与样本
- 法国药物警戒网络1985至2017年数据的回顾性药物警戒研究,共纳入69例DILAD患者。
- 病例还来自法国大疱性疾病研究组及法国药物皮肤不良反应研究者中参与的医师。
- 药物因果性采用法国归因法系统判定。
主要发现
- 69例中42%有黏膜受累,20%皮损模拟TEN,21%有嗜酸性粒细胞浸润,10%有角质形成细胞坏死。
- 80%病例直接免疫荧光显示孤立线状IgA沉积。
- 万古霉素在39例(57%)中被怀疑,其中11例出现TEN样皮损,而无万古霉素可疑的病例中仅3例出现。
- 33例单一可疑药物患者中85%内在归因评分为I4。
- 依诺肝素、米诺环素和多西环素为此前未发表的可疑药物。
关键数值与推荐
- 万古霉素可疑39例(57%),其中TEN样皮损11例,无万古霉素可疑者中TEN样皮损3例。
- 单一可疑药物33例中85%内在归因评分为I4。
- 所有患者均停用可疑药物,15例未接受任何治疗,31例一线治疗为局部糖皮质激素。
- 60例有随访资料者中52例缓解,4例复发,4例死亡,5例意外再暴露阳性。
临床怎么用
- 对疑似DILAD患者应系统评估可疑药物并采用规范归因方法判定因果性。
- 万古霉素相关病例需警惕更严重的TEN样临床表现。
- 停用可疑药物是处理基础,轻症可仅用局部糖皮质激素,多数患者可获缓解。
局限性
- 为回顾性研究,依赖药物警戒自发报告与医师报告数据。
- 部分患者随访资料不完整,60例有随访资料。
- 未设对照组,无法量化各药物导致DILAD的绝对风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Linear immunoglobin A (IgA) bullous dermatosis is a rare autoimmune dermatosis considered spontaneous or drug-induced (DILAD). We assessed all DILAD cases, determined the imputability score of drugs and highlighted suspected drugs. METHODS: Data for patients with DILAD were collected retrospectively from the French Pharmacovigilance network (from 1985 to 2017) and from physicians involved in the Bullous Diseases French Study Group and the French Investigators for Skin Adverse Reactions to Drugs. Drug causality was systematically determined by the French imputability method. RESULTS: Of the 69 patients, 42% had mucous membrane involvement, 20% lesions mimicking toxic epidermal necrolysis (TEN), 21% eosinophil infiltrates and 10% keratinocytes necrosis. Direct immunofluorescence, in 80%, showed isolated linear IgA deposits. Vancomycin (VCM) was suspected in 39 cases (57%), 11 had TEN-like lesions, as compared with three without VCM suspected. Among the 33 patients with a single suspected drug, 85% had an intrinsic imputability score of I4. Among them, enoxaparin, minocycline and vibramycin were previously unpublished. For all patients, the suspect drug was withdrawn; 15 did not receive any treatment. First-line therapy for 31 patients was topical steroids. Among the 60 patients with available follow-up, 52 achieved remission, 10 without treatment. Four patients experienced relapse, four died and five had positive accidental rechallenges. CONCLUSIONS: There is no major clinical difference between DILAD and idiopathic linear IgA bullous dermatosis, but the former features a higher prevalence of patients mimicking TEN. VCM, suspected in more than half of the cases, might be responsible for more severe clinical presentations. We report three new putative drugs.
引用
- Garel B, Ingen-Housz-Oro S, Afriat D, et al. Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases. Br J Clin Pharmacol. 2019. PMID: 30511379. doi:10.1111/bcp.13827
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。